Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Intra-Cellular Therapies stock | $43.13

Learn how to easily invest in Intra-Cellular Therapies stock.

Intra-Cellular Therapies Inc is a biotechnology business based in the US. Intra-Cellular Therapies shares (ITCI) are listed on the NASDAQ and all prices are listed in US Dollars. Intra-Cellular Therapies employs 383 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Intra-Cellular Therapies

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ITCI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Intra-Cellular Therapies stock price (NASDAQ: ITCI)

Use our graph to track the performance of ITCI stocks over time.

Intra-Cellular Therapies shares at a glance

Information last updated 2021-10-24.
Latest market close$43.13
52-week range$22.92 - $44.80
50-day moving average $37.29
200-day moving average $36.34
Wall St. target price$53.20
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.04

Buy Intra-Cellular Therapies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Intra-Cellular Therapies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intra-Cellular Therapies price performance over time

Historical closes compared with the close of $43.13 from 2021-10-22

1 week (2021-10-15) 9.75%
1 month (2021-09-24) 17.36%
3 months (2021-07-23) 19.36%
6 months (2021-04-23) 38.86%
1 year (2020-10-23) 65.25%
2 years (2019-10-24) 403.86%
3 years (2018-10-24) 170.41%
5 years (2016-10-24) 224.29%

Intra-Cellular Therapies financials

Revenue TTM $55.7 million
Gross profit TTM $-44,864,187
Return on assets TTM -28.08%
Return on equity TTM -50.88%
Profit margin 0%
Book value $6.81
Market capitalisation $3.5 billion

TTM: trailing 12 months

Shorting Intra-Cellular Therapies shares

There are currently 5.8 million Intra-Cellular Therapies shares held short by investors – that's known as Intra-Cellular Therapies's "short interest". This figure is 1.3% down from 5.8 million last month.

There are a few different ways that this level of interest in shorting Intra-Cellular Therapies shares can be evaluated.

Intra-Cellular Therapies's "short interest ratio" (SIR)

Intra-Cellular Therapies's "short interest ratio" (SIR) is the quantity of Intra-Cellular Therapies shares currently shorted divided by the average quantity of Intra-Cellular Therapies shares traded daily (recently around 416526.76767677). Intra-Cellular Therapies's SIR currently stands at 13.86. In other words for every 100,000 Intra-Cellular Therapies shares traded daily on the market, roughly 13860 shares are currently held short.

However Intra-Cellular Therapies's short interest can also be evaluated against the total number of Intra-Cellular Therapies shares, or, against the total number of tradable Intra-Cellular Therapies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intra-Cellular Therapies's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Intra-Cellular Therapies shares in existence, roughly 70 shares are currently held short) or 0.0949% of the tradable shares (for every 100,000 tradable Intra-Cellular Therapies shares, roughly 95 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Intra-Cellular Therapies.

Find out more about how you can short Intra-Cellular Therapies stock.

Intra-Cellular Therapies share dividends

We're not expecting Intra-Cellular Therapies to pay a dividend over the next 12 months.

Intra-Cellular Therapies share price volatility

Over the last 12 months, Intra-Cellular Therapies's shares have ranged in value from as little as $22.915 up to $44.8. A popular way to gauge a stock's volatility is its "beta".

ITCI.US volatility(beta: 1.12)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intra-Cellular Therapies's is 1.1175. This would suggest that Intra-Cellular Therapies's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Intra-Cellular Therapies overview

Intra-Cellular Therapies, Inc. , a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Frequently asked questions

What percentage of Intra-Cellular Therapies is owned by insiders or institutions?
Currently 4.946% of Intra-Cellular Therapies shares are held by insiders and 89.729% by institutions.
How many people work for Intra-Cellular Therapies?
Latest data suggests 383 work at Intra-Cellular Therapies.
When does the fiscal year end for Intra-Cellular Therapies?
Intra-Cellular Therapies's fiscal year ends in December.
Where is Intra-Cellular Therapies based?
Intra-Cellular Therapies's address is: 430 East 29th Street, New York, NY, United States, 10016
What is Intra-Cellular Therapies's ISIN number?
Intra-Cellular Therapies's international securities identification number is: US46116X1019
What is Intra-Cellular Therapies's CUSIP number?
Intra-Cellular Therapies's Committee on Uniform Securities Identification Procedures number is: 46116X101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site